The new facilities will support the increased demand for Optimer technology.Baroness Susan Greenfield opened the new site and presented on the challenges in scientific discovery
28 November, 2022
Over the last decade, co-crystallization has become an attractive alternative to improve the physiochemical properties of drugs without affecting their pharmacology. As a result of the pharmaceutical benefits co-crystals exhibit, industrial interest is on the rise. Here Dr. Thomas Kendall, application specialist at crystallization and solid-state specialist Technobis Crystallization Systems, gives a perspective on the benefits of co-crystals and explains how they can be screened.
24 November, 2022
Last week, Shionogi partnered with the Active Citizenship Network and members of the European Parliament (MEPs) to host an EU Parliament event calling for collaboration to drive policy change and implementation in the fight against antimicrobial resistance (AMR) within the EU and member states. Urgent action is needed to encourage and support the discovery and development of novel antibiotics as well as access models that reward innovation and appropriate use to address the growing threat of AMR.
21 November, 2022
98 per cent of exhibitors sign up for Lab Innovations 2023 after a record breaking event this year
17 November, 2022
Collaboration with innovative Finnish software company to explore how to reduce the time and cost of drug discovery and development using quantum computers
16 November, 2022
The team behind the success of one the country’s largest science and innovation park has announced its plans to grow and double the number of people employed on site as it celebrates a decade of delivering jobs and investment in the South East.
16 November, 2022
A discovery that may improve treatment options for patients with neurodegenerative diseases has been made by scientists at King’s College London and the University of Bath.
15 November, 2022
Stockholm, Sweden, November 8, 2022 – Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target.
11 November, 2022
Joint publication in Nature Chemistry between OMass Therapeutics’ scientists and co-founder Professor Dame Carol Robinson’s team at Oxford University. Data demonstrates the ability of native mass spectrometry (MS) to interrogate the pharmacology of the beta-1 adrenergic receptor (ß1AR), a G protein-coupled receptor (GPCR). Discovery of endogenous zinc ion as a positive allosteric modulator in well studied receptor exemplifies the potential of native MS to uncover novel insights that may be important for drug discovery
10 November, 2022
The topic of this month’s newsletter from Drug Discovery Today is “Drug Delivery”.
10 November, 2022
A team of surgeons and scientists from the UK, Sweden and Canada, funded by Rinri Therapeutics, has confirmed secure surgical access to the central core of the human cochlea The research, published in Scientific Reports, is critical to the first in-human trials of new cell, gene and drug therapies for the inner ear, and will assist with treatment for improving hearing loss and deafness over the long-term
10 November, 2022
Chemical manufacturer LCC has raised £2.2m of investment from a panel of regional investors, to expand its team and continue its global operation from the UK.
10 November, 2022
University of Bath spin-out hailed for revolutionary development to provide world’s first curative therapy for heart failure
03 November, 2022
Bowel cancer patients could in future benefit from a new 3D bioprinting technology which would use their own cells to replicate the complex cellular environment of solid tumours in 3D models. The University of Bristol-led advance, published in Biofabrication, would allow clinicians to treat the models, known as spheroids, with chemotherapy drugs and radiation to help them understand an individual patient’s resistance to therapies.
03 November, 2022
BOSTON, Mass. and Oxford, UK – November 2, 2022 – ROME Therapeutics and Enara Bio, two leading biotechnology companies focused on developing novel medicines driven by insights to the dark genome, today announced that they will host the inaugural Dark Genome Symposium on Monday, November 7, 2022 at ROME’s headquarters in Boston. This one-day event brings together leaders from academia, biotech and pharma working on the dark genome to share knowledge, opportunities, applications and challenges to solve as a community.
02 November, 2022